{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:27:05Z","timestamp":1784042825848,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.thromres.2018.08.018","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T22:59:01Z","timestamp":1535410741000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa"],"prefix":"10.1016","volume":"170","author":[{"given":"William E.","family":"Plautz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester I.","family":"Goldfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Samelson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya S.","family":"Pilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-5964","authenticated-orcid":false,"given":"Arani","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valder R.","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinku","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2018.08.018_bb0005","series-title":"Hemophilia B","author":"Konkle","year":"1993"},{"issue":"1","key":"10.1016\/j.thromres.2018.08.018_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/prot.22035","article-title":"Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX","volume":"73","author":"Chavali","year":"2008","journal-title":"Proteins"},{"issue":"12","key":"10.1016\/j.thromres.2018.08.018_bb0015","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678","article-title":"High levels of factor IX increase the risk of venous thrombosis","volume":"95","author":"van Hylckama Vlieg","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2018.08.018_bb0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2141.2001.03186.x","article-title":"Factor IX and thrombosis","volume":"115","author":"Lowe","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2018.08.018_bb0025","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1309\/AJCPAGOR4Q2IIKUG","article-title":"Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events","volume":"140","author":"Heikal","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.thromres.2018.08.018_bb0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0092-8674(93)90063-V","article-title":"Inherited predisposition to thrombosis","volume":"72","author":"Miletich","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.thromres.2018.08.018_bb0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.pop.2016.07.001","article-title":"Thrombosis, hypercoagulable states, and anticoagulants","volume":"43","author":"Hollenhorst","year":"2016","journal-title":"Prim. Care"},{"issue":"17","key":"10.1016\/j.thromres.2018.08.018_bb0040","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2018.08.018_bb0045","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1161\/ATVBAHA.112.250928","article-title":"Inhibition of intrinsic Xase by protein S: a novel regulatory role of protein S independent of activated protein C","volume":"32","author":"Chattopadhyay","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.thromres.2018.08.018_bb0050","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/ATVBAHA.117.310588","article-title":"Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis","volume":"38","author":"Plautz","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"16","key":"10.1016\/j.thromres.2018.08.018_bb0055","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJM200104193441607","article-title":"Genetic susceptibility to venous thrombosis","volume":"344","author":"Seligsohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.08.018_bb0060","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0049-3848(08)70021-5","article-title":"Protein S is a cofactor for tissue factor pathway inhibitor","volume":"122","author":"Rosing","year":"2008","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2018.08.018_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2007-1002683","article-title":"Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies","volume":"16","author":"Marlar","year":"1990","journal-title":"Semin. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2018.08.018_bb0070","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1160\/TH13-02-0154","article-title":"Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo","volume":"110","author":"Kao","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2018.08.018_bb0075","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"issue":"51","key":"10.1016\/j.thromres.2018.08.018_bb0080","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1021\/bi051469f","article-title":"Efficient thrombin generation requires molecular phosphatidylserine, not a membrane surface","volume":"44","author":"Majumder","year":"2005","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.thromres.2018.08.018_bb0085","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1021\/bi020017p","article-title":"Specificity of soluble phospholipid binding sites on human factor Xa","volume":"41","author":"Banerjee","year":"2002","journal-title":"Biochemistry"},{"issue":"33","key":"10.1016\/j.thromres.2018.08.018_bb0090","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1074\/jbc.M200893200","article-title":"Soluble phosphatidylserine triggers assembly in solution of a prothrombin-activating complex in the absence of a membrane surface","volume":"277","author":"Majumder","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.thromres.2018.08.018_bb0095","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/S0021-9258(19)39652-8","article-title":"Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation","volume":"265","author":"Krishnaswamy","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.thromres.2018.08.018_bb0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2144\/02323dd01","article-title":"Protein interaction-targeted drug discovery: evaluating critical issues","volume":"32","author":"Golemis","year":"2002","journal-title":"Biotechniques"},{"issue":"14","key":"10.1016\/j.thromres.2018.08.018_bb0105","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2009-02-203661","article-title":"Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite","volume":"114","author":"Buyue","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2018.08.018_bb0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2018.08.018_bb0115","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJM200012283432613","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Hari","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2018.08.018_bb0120","first-page":"89","article-title":"Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level","volume":"37","author":"Orstavik","year":"1985","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.thromres.2018.08.018_bb0125","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1538-7836.2006.02024.x","article-title":"Genetic determinants of normal variation in coagulation factor (F) IX levels: genome-wide scan and examination of the FIX structural gene","volume":"4","author":"Khachidze","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2018.08.018_bb0130","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1538-7836.2008.03066.x","article-title":"Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis","volume":"6","author":"van Minkelen","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.08.018_bb0135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.thromres.2018.08.018_bb0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1310\/hpj4805-366","article-title":"New oral anticoagulants for stroke prevention in atrial fibrillation: more choices bring more challenges","volume":"48","author":"Howard","year":"2013","journal-title":"Hosp. Pharm."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481830478X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481830478X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T16:21:01Z","timestamp":1693844461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938481830478X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"alternative-id":["S004938481830478X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.08.018","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}